这项对比试验由礼来赞助，其结果显示，使用Zepbound的患者在经过72周的治疗后体重平均减轻了20.2%（约50磅），而使用Wegovy的患者体重减轻了13.7%（约33磅）。① Eli Lilly announced on Wednesday that in a comparative trial, the weight loss effect of its weight loss drug Zepbound was higher than that of competitor Novo Nordisk's similar drug Wegovy; ② Eli Lilly is still evaluating the test results. The company said it plans to publish it in a peer-reviewed journal and at a medical conference next year.
Financial Services, December 4 (Editor: Xia Junxiong) US pharmaceutical giant Eli Lilly announced on Wednesday that in a comparative trial, the weight loss effect of its weight loss drug Zepbound was higher than that of competitor Novo Nordisk's similar drug Wegovy.
Affected by this news, Eli Lilly's US stock rose nearly 2% in the premarket.
The results of this comparative trial, sponsored by Eli Lilly, showed that patients using Zepbound lost an average of 20.2% (about 50 pounds) of body weight after 72 weeks of treatment, while those using Wegovy lost 13.7% (about 33 pounds) of weight.
The trial enrolled 751 patients who were obese or overweight, none of whom had diabetes. The participants were divided into two groups and injected with one of the drugs every week, gradually increasing the dose to the maximum tolerated dose.
Eli Lilly said that in comparison tests, Zepbound's relative weight reduction effect was 47% higher than Wegovy's. The company also claims that more than 31% of people who used Zepbound lost at least a quarter of their weight, while only about 16% of those who used Wegovy lost that much weight.
Eli Lilly is still evaluating the trial results, and the company said it plans to publish them in a peer-reviewed journal and at a medical conference next year.
This trial validates an earlier study. A study published in July this year showed that Eli Lilly's Mounjaro was able to lose weight faster and more effectively than Novartis and Nord's Ozempic.
Mounjaro and Zepbound have the same active ingredient, terpotide. The active cost of Ozempic and Wegovy is also the same, that is, simeglutide.
All four drugs are GLP-1 (glucagon-like peptide-1) drugs. The difference is that Mounjaro and Ozempic are approved to treat diabetes, while Zepbound and Wegovy focus on weight loss.
Novo Nordisk said on Wednesday that the company's clinical trials showed that compared to placebo, Wegovy can reduce the risk of heart attacks, strokes and other major cardiovascular diseases by 20%, and that this change is unrelated to weight changes.
“We know that treating this misunderstood disease is more than just numbers on the scale,” Novo Nordisk said.
For Lilly, Zepbound's more prominent weight loss effects may help it stay ahead of Novo Nordisk in the diet medicine market. Some analysts expect that by 2030, the annual sales of the global diet pills market may increase to around 130 billion US dollars.
